title: Interview with Johann de Bono for Future Oncology. Interviewed by Francesca Lake.
abstract: Johann de Bono speaks to Francesca Lake, Commissioning Editor. Johann de Bono leads the prostate cancer team at the Institute of Cancer Research (London, UK). He completed his PhD at the Beatson Institute of Cancer Research (Glasgow, UK) and was awarded a scholarship in 2000 that allowed him to undergo research on statistical issues in clinical trials for targeted drugs at the Cancer Research and Biostatistics SWOG Headquarters, a National Cancer Institute-supported organization at the Fred Hutchinson Cancer Center (WA, USA). He then spent 3 years working in the Institute of Drug Development in San Antonio (TX, USA), and then joined The Institute of Cancer Research and The Royal Marsden NHS Foundation trust in 2003. He has since been involved in developing over 100 new drugs, some of which are currently available to patients. One of these drugs is enzalutamide, which has recently been submitted for European marketing authorization following positive clinical trials.
authors.forename: Johann
authors.initials: J
authors.lastname: de Bono
mesh_terms: D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000639:trends*; D058990:Molecular Targeted Therapy; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D012106:Research